Skip to main content
The word LIFE featuring images of KISQALI patients inside the letters

Click here for important information regarding nitrosamine impurity levels related to investigational use of ribociclib in early breast cancer.

There is controversy on the choice of CDK4/6i as there are no head-to-head comparisons between the agents and there are some differences in the study populations in the phase III randomized studies.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.

MONALEESA-2, statistically significant overall survival in 1L postmenopausal patients: At a median follow-up of 80 months, median OS was 63.9 months with KISQALI + letrozole (95% CI: 52.4-71.0) vs 51.4 months with letrozole (95% CI: 47.2-59.7); HR=0.765 (95% CI: 0.628-0.932); P=0.004. PFS was the primary end point.2-5

Video thumbnail

An expert discusses proven overall survival across 3 phase III trials in patients with HR+/HER2- mBC

“To have now a significant prolongation of overall survival and reaching the...5-year mark in overall survival in breast cancer is amazing.” —Gabriel Hortobagyi, MD

Explore data proven across 3 phase III trials

KISQALI Access Support Guide

KISQALI Access Support Guide

Clinical and treatment guidelines to support the insurance coverage process for KISQALI. Includes checklists and sample letters for following up on requests to health plans, and links to help patients get started on and afford their KISQALI treatment.
KISQALI resources

Downloadable Resources

Novartis strives to ensure you have everything you need to provide the best care for your patients. Explore our library of resources designed to support you, your staff, and your patients. These tools contain useful information that can help your patients get started and stay on treatment with KISQALI.

1L=first line; AI=aromatase inhibitor; CDK=cyclin-dependent kinase; ET=endocrine therapy; HR=hazard ratio; mBC=metastatic breast cancer; OS=overall survival; PFS=progression-free survival.

References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Published February 7, 2023. Accessed February 10, 2023. To view the most recent and complete version of the guideline, go online to 2. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med. 2022;386(10):942-950. doi:10.1056/NEJMoa2114663 3. Data on file. Novartis Pharmaceuticals Corp; 2021. 4. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375(18):1738-1748. doi:10.1056/NEJMoa1609709 5. Kisqali. Prescribing information. Novartis Pharmaceuticals Corp.